Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME

被引：0

作者：

Toural, E. ^{[1
]}

Ridderstrale, M. ^{[2
]}

Fitchett, D. ^{[3
]}

Kis, S. Giljanovic ^{[4
]}

Woerle, H. -J. ^{[5
]}

Mattheus, M. ^{[5
]}

Zinman, B. ^{[6
,7
]}

Inzucchi, S. E. ^{[8
]}

机构：

[1] Ctr Salud Lavapies, Madrid, Spain

[2] Steno Diabet Ctr, Gentofte, Denmark

[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[4] Eli Lilly Suisse SA, Representat Off, Zagreb, Croatia

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[6] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[7] Univ Toronto, Div Endocrinol, Toronto, ON, Canada

[8] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA

来源：

DIABETOLOGIA | 2016年 / 59卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1130

引用

页码：S539 / S540

页数：2

共 50 条

[1] Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG Outcome
Ridderstrale, Martin
Toural, Elvira
Fitchett, David
Kis, Sanja Giljanovic
Woerle, Hans J.
Mattheus, Michaela
Zinman, Bernard
Inzucchi, Silvio E.
DIABETES, 2016, 65 : A289 - A290
[2] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
Ridderstrale, M.
Fitchett, D.
Kis, S. Giljanovic
Woerle, H. J.
Mattheus, M.
Zinman, B.
Inzucchi, S.
EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
[3] EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR DEATH IN SUBGROUPS BYAGE: RESULTS FROM EMPA-REG OUTCOME
D'Emden, M.
Fitchett, D.
Kis, Giljanovic S.
Woerle, H.
Zinman, B.
Inzucchi, S.
NEPHROLOGY, 2016, 21 : 58 - 58
[4] Effect of empagliflozin on nephropathy in subgroups by age: results from EMPA-REG OUTCOME
von Eynatten, M.
Bergenstal, R. M.
Calabro, P.
Maldonado-Lutomirsky, M.
Mattheus, M.
Lachin, J. M.
Wanner, C.
DIABETOLOGIA, 2016, 59 : S483 - S483
[5] Effect of Empagliflozin on Nephropathy in Subgroups by Age: Results from EMPA-REG Outcome
Bergenstal, Richard M.
Calabro, Paolo
Lutomirsky, Mario Maldonado
Von Eynatten, Maximillian
Mattheus, Michaela
Wanner, John Lachin Christoph
DIABETES, 2016, 65 : A314 - A314
[6] EFFECT OF EMPAGLIFLOZIN ON NEPHROPATHY IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
D'Emden, M.
Bergenstal, R.
Lutomirsky, Maldonado M.
Wanner, C.
NEPHROLOGY, 2016, 21 : 59 - 59
[7] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
Monteiro, P.
Schaper, N.
Clark, D.
Hantel, S.
Woerle, H. J.
Inzucchi, S. E.
Fitchett, D.
EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192
[8] Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG Outcome
Monteiro, Pedro
Schaper, Nicolaas
Clark, Douglas
Hantel, Stefan
Woerle, Hans J.
Inzucchi, Silvio E.
Fitchett, David
DIABETES, 2016, 65 : A291 - A291
[9] EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
Lee, Dae Wook
Monteiro, Pedro
Clark, Douglas
Hantel, Stefan
Woerle, Hans J.
Inzucchi, Silvio E.
Fitchett, David
JOURNAL OF HYPERTENSION, 2016, 34 : E520 - E520
[10] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
Monteiro, P.
Schaper, N.
Clark, D.
Hantel, S.
Woerle, H. -J.
Inzucchi, S. E.
Fitchett, D.
DIABETOLOGIA, 2016, 59 : S534 - S534

← 1 2 3 4 5 →